Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT02904954 trial: what clinicians have said so far
Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer
- NCT02904954 ↗
- Completed
- Weill Medical College of Cornell University
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT02904954 (stage I, II and IIIA NSCLC) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02904954 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase 2 Trial of Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II, and IIIA Non-small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Durvalumab; Durvalumab plus SBRT
- Arms
- Arm 1 (Durvalumab monotherapy) · Experimental
- Arm 2 (Durvalumab plus SBRT) · Experimental
- Enrollment
- 60
- Primary outcomes
- Number of Subjects With Major Pathological Response (MPR)
- Sponsor
- Weill Medical College of Cornell University with AstraZeneca
- Start
- Dec 2, 2016
- Primary completion
- Sep 16, 2020
- Results posted
- Yes
- Registry record
- NCT02904954 · updated Oct 11, 2023
Publications
linked from the registry- Altorki NK, Walsh ZH, Melms JC, Port JL, Lee BE, Nasar A, Spinelli C, Caprio L, Rogava M, Ho P, Christos PJ, Saxena A, Elemento O, Bhinder B, Ager C, Amin AD, Sanfilippo NJ, Mittal V, Borczuk AC, Formenti SC, Izar B, McGraw TE. Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial. Nat Commun. 2023 Dec 19;14(1):8435. doi: 10.1038/s41467-023-44195-x. PubMed 38114518
- Lee B, Mynard N, Nasar A, Villena-Vargas J, Chow O, Harrison S, Stiles B, Port J, Altorki N. Surgical resection after neoadjuvant durvalumab and radiation is feasible and safe in non-small cell lung cancer: Results from a randomized trial. J Thorac Cardiovasc Surg. 2023 Jan;165(1):327-334.e2. doi: 10.1016/j.jtcvs.2022.07.017. Epub 2022 Aug 6. PubMed 36028357
- Altorki NK, McGraw TE, Borczuk AC, Saxena A, Port JL, Stiles BM, Lee BE, Sanfilippo NJ, Scheff RJ, Pua BB, Gruden JF, Christos PJ, Spinelli C, Gakuria J, Uppal M, Binder B, Elemento O, Ballman KV, Formenti SC. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncol. 2021 Jun;22(6):824-835. doi: 10.1016/S1470-2045(21)00149-2. Epub 2021 May 18. PubMed 34015311